- Home
- AVBP vs IMTX Comparison
AVBP vs IMTX Comparison
Compare AVBP & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVBP
- IMTX
- Stock Information
- Founded
- AVBP 2021
- IMTX N/A
- Country
- AVBP United States
- IMTX Germany
- Employees
- AVBP N/A
- IMTX N/A
- Industry
- AVBP
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVBP
- IMTX Health Care
- Exchange
- AVBP NYSE
- IMTX Nasdaq
- Market Cap
- AVBP 617.4M
- IMTX 579.8M
- IPO Year
- AVBP 2024
- IMTX N/A
- Fundamental
- Price
- AVBP $20.15
- IMTX $4.24
- Analyst Decision
- AVBP Strong Buy
- IMTX Strong Buy
- Analyst Count
- AVBP 6
- IMTX 4
- Target Price
- AVBP $39.00
- IMTX $16.67
- AVG Volume (30 Days)
- AVBP 162.5K
- IMTX 426.9K
- Earning Date
- AVBP 05-20-2025
- IMTX 05-20-2025
- Dividend Yield
- AVBP N/A
- IMTX N/A
- EPS Growth
- AVBP N/A
- IMTX N/A
- EPS
- AVBP N/A
- IMTX 0.14
- Revenue
- AVBP N/A
- IMTX $161,336,577.00
- Revenue This Year
- AVBP $63.13
- IMTX N/A
- Revenue Next Year
- AVBP N/A
- IMTX $4.92
- P/E Ratio
- AVBP N/A
- IMTX $29.25
- Revenue Growth
- AVBP N/A
- IMTX 188.60
- 52 Week Low
- AVBP $15.47
- IMTX $3.30
- 52 Week High
- AVBP $36.37
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- AVBP 51.13
- IMTX 43.11
- Support Level
- AVBP $18.84
- IMTX $3.94
- Resistance Level
- AVBP $21.79
- IMTX $5.41
- Average True Range (ATR)
- AVBP 1.12
- IMTX 0.35
- MACD
- AVBP 0.00
- IMTX -0.04
- Stochastic Oscillator
- AVBP 44.50
- IMTX 20.41
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.